Tiziana Life Sciences Ltd (NASDAQ:TLSA) announced that Executive Chairman and Founder Gabriele Cerrone purchased 15,000 shares at $1.55 each, increasing his total holding to 43,252,143 shares, or 37.02% of the company’s issued share capital.
Tiziana is developing intranasal foralumab, a fully human anti-CD3 monoclonal antibody for immunomodulation therapies.